Hansen Pharm ranks among the top 10 pharmaceutical manufacturers of China, featuring the research, development and manufacture of new generic drugs which cover five therapeutic categories- anticancer, anti-diabetics, central nervous system (CNS), gastro-intestinal and antibiotics. While achieving great success domestically, through direct and strengthened involvement, Hansen is gaining steadily in international market and its drug products have been warmly accepted by customers all over the world. Always dynamic and flexible, Hansen's quality system complies with the strict regulatory requirements of leading health authorities. By end of 2005, all the API and formulation drugs of Hansen have been granted cGMP certificates by SFDA. In October of 2003, VInorelbine tartrate, one of Hansen's anticancer APIs, was inspected and approved by US FDA. Backed by strong R&D teams, Hansen Pharm continues to be at the forefront of the life-science industry of China. Currently, Hansen Pharm has 16 new chemical compounds under development, including nearly half in phase II and phase III of clinic studies.
